Article

Mylan Inc. accused of patent infringement

Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.

New York-Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.

According to Alcon’s suit, filed in Delaware federal court July 26, Mylan has attempted to get the FDA to sign off on its abbreviated new drug application for eye drops containing the active ingredient travoprost-a product Alcon claimed is almost identical to its glaucoma treatment Travatan Z, a product launched in 2006 which aims to reduce the pressure caused by ocular fluids inside the eyes -before the patents, which are less than 1 year old, had expired.

In the suit, Alcon also accused Mylan of frequently attempting to copy others’ intellectual property by filing ANDA’s in which the generic-drug maker certified that patents were invalid or would not be infringed by its proposed pharmaceuticals.

According to the suit, “litigating patents covering FDA-approved branded drug products is a central feature of Mylan Inc. and Mylan Pharmaceuticals’ business model.”

The suit is asking the court to impose an injunction barring Mylan from making or selling its glaucoma drug until the latest of Alcon’s patents expire and any additional exclusivity periods expire.

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.